Real-world dapagliflozin efficacy mirrors clinical trial findings
medwireNews: Dapagliflozin delivers reductions in glycated hemoglobin (HbA1c), blood pressure, and weight in patients with type 2 diabetes treated for 2 years in primary care, shows a study of patients in the UK’s Clinical Practice Research Datalink.
The average reduction in HbA1c among 5858 patients, aged an average of 58.2 years with a diabetes duration of 9.6 years, was 9.5 mmol/mol during the first 3 months of treatment, improving to 12.2 mmol/mol between 18 and 24 months. The largest average reduction, of 13.4 mmol/mol, occurred between 6 and 12 months of treatment.
There were also significant reductions in weight, averaging 4.8 kg by the end of the observation period, and in blood pressure, of 2.6/1.4 mmHg.
John Wilding (University Hospital Aintree, Liverpool, UK) and co-researchers note that nearly a third (n=1737) of the cohort were given dapagliflozin off-label (according to European regulations at the time). Almost a third of these patients had impaired kidney function, which the team says may reflect physicians’ familiarity with prescribing metformin to such patients, prior to the recent relaxing of the restrictions.
“No clinically meaningful differences in outcome were seen when comparing the overall and on-label cohorts in the present study, providing some external validity for efficacy in a more representative sample of the UK population than that enrolled in [randomized controlled trials],” they write in Primary Care Diabetes.
medwireNews is an independent medical news service provided by Springer Healthcare. © 2017 Springer Healthcare part of the Springer Nature group